Payment overview · 2025
General Payments
$305.68
14 reported records · 11 companies
Healthcare provider profile · identity verified
Humayun Abbas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MODESTO, CA · NPI 1336136548
Verified facts
What the public records show
CMS Open Payments records show Humayun Abbas, MD received $305.68 in general payments during 2025 across 14 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 14.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.86 | 14.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.60 | 11.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.51 | 10.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $30.95 | 10.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.03 | 9.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.38 | 9.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $26.36 | 8.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.33 | 7.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.84 | 6.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.47 | 6.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.35 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $305.68 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.86 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $35.60 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $31.51 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.51 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.51 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $30.95 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.03 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 38 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 134 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
134 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
215 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 794 | 230 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 722 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 567 | 157 |
| Omeprazole | Omeprazole | 436 | 119 |
| Gabapentin | Gabapentin | 424 | 99 |
| Lisinopril | Lisinopril | 422 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 420 | 120 |
| Metformin Hcl | Metformin Hcl | 397 | 115 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 349 | 109 |
| Losartan Potassium | Losartan Potassium | 334 | 100 |
| Tamsulosin Hcl | Tamsulosin Hcl | 327 | 99 |
| Furosemide | Furosemide | 296 | 81 |
| Alprazolam | Alprazolam | 269 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 226 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 63 |
| Simvastatin | Simvastatin | 217 | 53 |
| Eliquis | Apixaban | 215 | 45 |
| Trazodone Hcl | Trazodone Hcl | 206 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 199 | 54 |
| Ibuprofen | Ibuprofen | 194 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 165 | 33 |
| Lorazepam | Lorazepam | 163 | 36 |
| Cephalexin | Cephalexin | 159 | 110 |
| Baclofen | Baclofen | 155 | 46 |
| Potassium Chloride | Potassium Chloride | 151 | 45 |
| Allopurinol | Allopurinol | 136 | 35 |
| Sertraline Hcl | Sertraline Hcl | 136 | 34 |
| Glimepiride | Glimepiride | 135 | 40 |
| Ozempic | Semaglutide | 134 | 29 |
| Alendronate Sodium | Alendronate Sodium | 133 | 37 |
| Prednisone | Prednisone | 130 | 76 |
| Escitalopram Oxalate | Escitalopram Oxalate | 123 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 35 |
| Donepezil Hcl | Donepezil Hcl | 110 | 37 |
| Metformin Hcl Er | Metformin Hcl | 110 | 38 |
| Carvedilol | Carvedilol | 109 | 35 |
| Azithromycin | Azithromycin | 104 | 79 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 100 | 76 |
| Famotidine | Famotidine | 100 | 27 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 96 | 54 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 96 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 21 |
| Clonazepam | Clonazepam | 90 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 33 |
| Enalapril Maleate | Enalapril Maleate | 88 | 26 |
| Lovastatin | Lovastatin | 86 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 82 | 63 |
| Atenolol | Atenolol | 81 | 25 |
| Finasteride | Finasteride | 81 | 22 |
| Farxiga | Dapagliflozin Propanediol | 78 | 17 |
| Montelukast Sodium | Montelukast Sodium | 78 | 30 |
| Testosterone Cypionate | Testosterone Cypionate | 76 | 13 |
| Levofloxacin | Levofloxacin | 71 | 43 |
| Estradiol | Estradiol | 70 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 67 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 13 |
| Propranolol Hcl | Propranolol Hcl | 63 | 15 |
| Glipizide | Glipizide | 62 | 19 |
| Tramadol Hcl | Tramadol Hcl | 62 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 21 |
| Latanoprost | Latanoprost | 60 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 13 |
| Pregabalin | Pregabalin | 54 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 11 |
| Terazosin Hcl | Terazosin Hcl | 54 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 13 |
| Januvia | Sitagliptin Phosphate | 49 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 48 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 38 |
| Meclizine Hcl | Meclizine Hcl | 46 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 14 |
| Clonidine Hcl | Clonidine Hcl | 43 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | 11 |
| Buspirone Hcl | Buspirone Hcl | 40 | 16 |
| Fluconazole | Fluconazole | 40 | 20 |
| Terbinafine Hcl | Terbinafine Hcl | 40 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 14 |
| Jardiance | Empagliflozin | 38 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 32 |
| Temazepam | Temazepam | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Linzess | Linaclotide | 32 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 12 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Acyclovir | Acyclovir | 30 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 24 |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Metronidazole | Metronidazole | 27 | 22 |
| Naproxen | Naproxen | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 12 |
| Clonidine | Clonidine | 24 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 24 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Indomethacin | Indomethacin | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | 12 |
| Promethazine-Dm | Promethazine/Dextromethorphan | 22 | 18 |
| Risperidone | Risperidone | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Galantamine Er | Galantamine Hbr | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Methadone Hcl | Methadone Hcl | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Benzonatate | Benzonatate | 17 | 13 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $305.68 · 14 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ABRYSVO, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, GARDASIL 9, JARDIANCE, LEQVIO, M-M-R II, MOUNJARO, Ozempic, PREVNAR 20, PROCLAIM, Rybelsus, SHINGRIX, SPINRAZA, TZIELD | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error